Discontinuation of methotrexate in rheumatoid arthritis patients achieving clinical remission by treatment with upadacitinib plus methotrexate (DOPPLER study): Study protocol for an interventional, multicenter, open-label and single-arm clinical trial with clinical, ultrasound and biomarker assessments

Kawakami Atsushi0 个研究点目标入组 155 人开始时间: 2021年1月12日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1. Patients with 18 years older at the time of obtaining informed consent.
•2. Patients with rheumatoid arthritis (RA) fulfilled the ACR/EULAR classification criteria for RA (2010).
•3. Patients with moderate or more disease activity (DAS28-CRP > 3.2) at the time of the eligibility evaluation.
•4. Patients have >= 1 power Doppler (PD) positive joint (of 22 examined using musculoskeletal ultrasound (MSUS)) at the time of the eligibility evaluation.
•5. Patients who have received MTX treatment .
•6. Patients who can personally provide written consent at their own free will after being receiving a thorough explanation of the study and fully understanding their participation in the study.

•1. Patients treated with more than 7.5 mg per day of prednisolone.
•2. Patients with contraindications to upadacitinib
•3. Patients treated with two or more JAK inhibitors previously.
•4. Patients treated with upadacitinib previously.
•5. Patients with concurrent illness causing musculoskeletal disorders other than RA (ie, ankylosing spondylitis, reactive arthritis, psoriatic arthritis, crystal-induced arthritis, systemic lupus erythematosus, systemic scleroderma, inflammatory myopathy, and mixed connective tissue disease).
•6. Women who are currently pregnant or will not be compliant with a medically approved contraceptive regimen during and 12 months after the study period and lactating women. Men who will not be compliant with a contraceptive regimen during and 12 months after the study period.
•7. Patients who jugged unsuitable for this study by the investigator.Patients who jugged unsuitable for this study by the investigator .

发起方